PT866720E - Proteina ob para aumentar a massa do tecido mole - Google Patents

Proteina ob para aumentar a massa do tecido mole

Info

Publication number
PT866720E
PT866720E PT96938773T PT96938773T PT866720E PT 866720 E PT866720 E PT 866720E PT 96938773 T PT96938773 T PT 96938773T PT 96938773 T PT96938773 T PT 96938773T PT 866720 E PT866720 E PT 866720E
Authority
PT
Portugal
Prior art keywords
protein
increase mass
mole
increasing
tissue
Prior art date
Application number
PT96938773T
Other languages
English (en)
Inventor
Christopher Francis Toombs
Michael Benjamin Mann
Mary Ann Pelleymounter
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of PT866720E publication Critical patent/PT866720E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT96938773T 1995-11-22 1996-11-04 Proteina ob para aumentar a massa do tecido mole PT866720E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US56173295A 1995-11-22 1995-11-22

Publications (1)

Publication Number Publication Date
PT866720E true PT866720E (pt) 2004-06-30

Family

ID=24243198

Family Applications (1)

Application Number Title Priority Date Filing Date
PT96938773T PT866720E (pt) 1995-11-22 1996-11-04 Proteina ob para aumentar a massa do tecido mole

Country Status (15)

Country Link
EP (3) EP1285664B1 (pt)
JP (2) JP4173914B2 (pt)
AT (2) ATE455554T1 (pt)
AU (3) AU7607496A (pt)
CA (2) CA2358862A1 (pt)
DE (2) DE69631544T2 (pt)
DK (1) DK0866720T3 (pt)
ES (2) ES2339846T3 (pt)
IL (2) IL124442A0 (pt)
MX (1) MX9803992A (pt)
NZ (3) NZ511617A (pt)
PT (1) PT866720E (pt)
SI (1) SI0866720T1 (pt)
WO (1) WO1997018833A1 (pt)
ZA (1) ZA969605B (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US20030040467A1 (en) 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
CA2358862A1 (en) * 1995-11-22 1997-05-29 Amgen Inc. Methods of increasing lean tissue mass using ob protein compositions
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
US20050019325A1 (en) 1996-01-08 2005-01-27 Carter Paul J. WSX receptor agonist antibodies
US6541604B1 (en) 1996-01-08 2003-04-01 Genentech, Inc. Leptin receptor having a WSX motif
US7074397B1 (en) 1996-01-08 2006-07-11 Genentech, Inc. Method for enhancing proliferation or differentiation of a cell using ob protein
AU2246097A (en) * 1996-01-25 1997-08-20 Eli Lilly And Company Obesity protein analog compounds and formulations thereof
JP2000509377A (ja) * 1996-04-19 2000-07-25 ザイモジェネティクス，インコーポレイティド 骨形成を誘発するための方法
CA2274799A1 (en) * 1996-12-20 1998-07-02 Eli Lilly And Company Anti-obesity proteins
CA2275183A1 (en) * 1996-12-20 1998-07-02 Amgen Inc. Ob fusion protein compositions and methods
US20020019352A1 (en) * 1997-04-17 2002-02-14 David N. Brems Stable, active, human ob protein compositions and methods
EP0950417A3 (en) 1998-02-23 2000-02-23 Pfizer Products Inc. Treatment of skeletal disorders
WO1999053939A1 (en) * 1998-04-20 1999-10-28 Mayo Foundation For Medical Education And Research Treatment of osteoporosis with leptin
US6210924B1 (en) 1998-08-11 2001-04-03 Amgen Inc. Overexpressing cyclin D 1 in a eukaryotic cell line
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
WO2000024418A1 (en) * 1998-10-27 2000-05-04 Eli Lilly And Company Prevention of muscle mass loss with leptin receptor ligands
ATE323766T1 (de) * 1999-02-12 2006-05-15 Amgen Inc Glykosylierte leptinzusammensetzungen und zugehörige verfahren
US8106098B2 (en) 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
JP2005506994A (ja) 2001-10-22 2005-03-10 アムジェン インコーポレイテッド ヒト脂肪組織萎縮症を処置するためのレプチンの使用および該処置のための素因決定方法
ATE486842T1 (de) 2002-03-12 2010-11-15 Merck Sharp & Dohme Substituierte amide
CA2571292C (en) * 2004-06-30 2013-05-21 Nektar Therapeutics Al, Corporation Polymer-factor ix moiety conjugates
US8394765B2 (en) 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
ES2325773T5 (es) 2004-11-01 2014-02-24 Amylin Pharmaceuticals, Llc. Tratamiento de la obesidad y de los trastornos relacionados
WO2008048691A2 (en) * 2006-10-18 2008-04-24 Amylin Pharmaceuticals, Inc. Use of leptin for treating post-lipectomy ectopic fat deposition and other post-lipectomy associated disorders
US8501686B2 (en) 2008-06-05 2013-08-06 University Of Michigan Method of treating fatty liver diseases and conditions in non-lipodystrophic subjects
JP2014502252A (ja) 2010-09-28 2014-01-30 アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー 作用持続時間が増した改変ポリペプチド
US9968575B2 (en) 2012-09-27 2018-05-15 The Children's Medical Center Corporation Compounds for the treatment of obesity and methods of use thereof
HRP20190219T1 (hr) 2013-11-26 2019-03-22 The Children's Medical Center Corporation Spojevi za tretman pretilosti i postupci za njihovu uporabu
US20170209408A1 (en) 2014-04-03 2017-07-27 The Children's Medical Center Corporation Hsp90 inhibitors for the treatment of obesity and methods of use thereof
PL3509624T3 (pl) 2016-09-12 2024-03-25 Amryt Pharmaceuticals Inc. Sposób wykrywania przeciwciał neutralizujących przeciwko leptynie

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1228925B (it) * 1987-08-07 1991-07-10 Eniricerche Spa Procedimento per la preparazione dell'ormone della crescita umano
DK173142B1 (da) * 1988-08-24 2000-02-07 Natinco Nv Fremgangsmåde til forbedring af kødkvaliteten og foderomsætningseffektiviteten for grise
US5028440A (en) * 1990-01-30 1991-07-02 Iowa State University Research Foundation, Inc. Method of raising meat producing animals to increase lean tissue development
KR960703759A (ko) * 1993-08-13 1996-08-31 하르트무트 벤케르트 대형 물체의 표면 처리공정 및 장치(process and device for treating the surface of large objects)
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
GB9511935D0 (en) * 1995-06-13 1995-08-09 Smithkline Beecham Plc Novel compound
CA2358862A1 (en) * 1995-11-22 1997-05-29 Amgen Inc. Methods of increasing lean tissue mass using ob protein compositions
RU2178307C2 (ru) * 1995-12-27 2002-01-20 Джинентех Инк. Производные ов-протеина
CA2275183A1 (en) * 1996-12-20 1998-07-02 Amgen Inc. Ob fusion protein compositions and methods
CN1202862C (zh) * 1997-04-17 2005-05-25 安姆根有限公司 包含具有抗体Fc链的稳定、有活性人OB蛋白的结合物的组合物及方法

Also Published As

Publication number Publication date
NZ511617A (en) 2003-08-29
JP4227325B2 (ja) 2009-02-18
IL127926A (en) 2006-08-20
NZ512083A (en) 2003-02-28
CA2236163A1 (en) 1997-05-29
WO1997018833A1 (en) 1997-05-29
ATE259243T1 (de) 2004-02-15
JP2002206000A (ja) 2002-07-23
ZA969605B (en) 1997-06-02
EP1285664A3 (en) 2003-07-30
JP2000500492A (ja) 2000-01-18
EP0866720B1 (en) 2004-02-11
NZ527007A (en) 2005-01-28
EP0866720A1 (en) 1998-09-30
JP4173914B2 (ja) 2008-10-29
ATE455554T1 (de) 2010-02-15
EP1285664A2 (en) 2003-02-26
MX9803992A (es) 1998-09-30
DK0866720T3 (da) 2004-06-14
AU763755B2 (en) 2003-07-31
DE69631544T2 (de) 2004-12-23
EP1285664B1 (en) 2010-01-20
ES2217327T3 (es) 2004-11-01
SI0866720T1 (en) 2004-10-31
ES2339846T3 (es) 2010-05-26
AU4265200A (en) 2000-09-21
AU763769B2 (en) 2003-07-31
AU4265300A (en) 2000-09-07
AU7607496A (en) 1997-06-11
CA2358862A1 (en) 1997-05-29
IL127926A0 (en) 1999-11-30
DE69631544D1 (de) 2004-03-18
IL124442A0 (en) 1998-12-06
DE69638119D1 (de) 2010-03-11
EP0956862A1 (en) 1999-11-17

Similar Documents

Publication Publication Date Title
ATE259243T1 (de) Fettleibigkeitsprotein (ob) zur erhögung der mageren körpermasse
ATE178907T1 (de) Rezeptorbindende region des diphtherietoxius
FR12C0004I2 (fr) Anticorps contre l'antigene ctla-4 humain et utilisation
DE69723710D1 (de) Medizinische instrumente mit verbesserter elastizität
DE69621260D1 (de) Biokompatible hydrophile gleitmittel fur medizinische instrumente
DE69533544D1 (de) Inhibitoren des humanplasmins, die sich von den kunitz domänen ableiten
DE69602111D1 (de) Chirurgisches Penetrationsinstrument
DE69435105D1 (de) Derivate therapeutischer Peptide
SE9500566L (sv) L-platta
NL300273I1 (nl) DNA dat humaan papillomavirus type 18 codeert.
ES2133813T3 (es) Cadenas de lamininas: diagnostico y uso terapeutico.
BR9404567A (pt) Peça de implante dentário ósseo individual
EP0804562A4 (en) CONTAINING TISSUE GROWTH FACTOR-2
IT1238825B (it) Dispositivo per la correzione chirurgica dell'ametropia.
EA200100700A1 (ru) Гены и белки и их применение
DE69735039D1 (de) Acetylhydrolase des Plättchen aktivierenden Faktors, und entsprechendes Gen
ATE314861T1 (de) Verwendung von antikörper gegen mag zur behandlung ischämischer schlaganfälle
SE9803962D0 (sv) Nucleic acid encoding a nervous tissue sodium channel
DE69831223D1 (de) Gefriergetrocknete zusammensetzung des menschlichen,morphogenen knochenproteins mp52
DE69409961D1 (de) Triarylethylenderivate zur therapeutischen verwendung
ATE407944T1 (de) Mit trp-proteinen verwandtes protein mtr1 und dieses codierende dna-sequenz
EA199900006A1 (ru) Препарат и способ для лечения застоной сердечной недостаточности
PT878195E (pt) Utilizacao de um composto 2-aroil-3-arilbenzo(b)tiofeno para a reducao de fibrinogenio
DK0795008T3 (da) Humane hypertrofe chondrocyt-cellelinjer
AU8499501A (en) Slo2 and slo4, novel potassium channel proteins from human brain